Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Public ClinicalTrials.gov record NCT07764978. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.
Study identification
- NCT ID
- NCT07764978
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 750 participants
Conditions and interventions
Conditions
Interventions
- AZD0120 Biological
- Bortezomib Drug
- Cyclophosphamide Drug
- Daratumumab Biological
- Dexamethasone Drug
- Fludarabine Drug
- Isatuximab Biological
- Lenalidomide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2026
- Primary completion
- Jan 10, 2029
- Completion
- May 11, 2034
- Last update posted
- Aug 13, 2026
2026 – 2034
United States locations
- U.S. sites
- 45
- U.S. states
- 24
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | 85234 | Not yet recruiting |
| Research Site | Phoenix | Arizona | 85054 | Not yet recruiting |
| Research Site | Tucson | Arizona | 85719 | Not yet recruiting |
| Research Site | Orange | California | 92868 | Not yet recruiting |
| Research Site | Santa Monica | California | 90404 | Not yet recruiting |
| Research Site | Aurora | Colorado | 80045 | Not yet recruiting |
| Research Site | Denver | Colorado | 80218 | Not yet recruiting |
| Research Site | New Haven | Connecticut | 06510 | Not yet recruiting |
| Research Site | Coral Gables | Florida | 33156 | Not yet recruiting |
| Research Site | Tampa | Florida | 33606 | Not yet recruiting |
| Research Site | Atlanta | Georgia | 30322 | Not yet recruiting |
| Research Site | Chicago | Illinois | 60607 | Not yet recruiting |
| Research Site | Iowa City | Iowa | 52242 | Not yet recruiting |
| Research Site | Wichita | Kansas | 67214 | Not yet recruiting |
| Research Site | Louisville | Kentucky | 40207 | Not yet recruiting |
| Research Site | Baton Rouge | Louisiana | 70809 | Not yet recruiting |
| Research Site | Baltimore | Maryland | 21201 | Not yet recruiting |
| Research Site | Detroit | Michigan | 48201 | Not yet recruiting |
| Research Site | St Louis | Missouri | 63110 | Not yet recruiting |
| Research Site | East Brunswick | New Jersey | 08816 | Not yet recruiting |
| Research Site | Albany | New York | 12208 | Not yet recruiting |
| Research Site | New Hyde Park | New York | 11042 | Not yet recruiting |
| Research Site | New York | New York | 10016 | Not yet recruiting |
| Research Site | New York | New York | 10029 | Not yet recruiting |
| Research Site | New York | New York | 10032 | Not yet recruiting |
| Research Site | The Bronx | New York | 10467 | Not yet recruiting |
| Research Site | Chapel Hill | North Carolina | 27599 | Not yet recruiting |
| Research Site | Charlotte | North Carolina | 28203 | Not yet recruiting |
| Research Site | Durham | North Carolina | 27705 | Not yet recruiting |
| Research Site | Winston-Salem | North Carolina | 27103 | Not yet recruiting |
| Research Site | Winston-Salem | North Carolina | 27157 | Not yet recruiting |
| Research Site | Cincinnati | Ohio | 45236 | Not yet recruiting |
| Research Site | Cleveland | Ohio | 44195 | Not yet recruiting |
| Research Site | Columbus | Ohio | 43210 | Not yet recruiting |
| Research Site | Montgomery | Ohio | 45242 | Not yet recruiting |
| Research Site | Portland | Oregon | 97239 | Not yet recruiting |
| Research Site | Nashville | Tennessee | 37203 | Not yet recruiting |
| Research Site | Nashville | Tennessee | 37219 | Not yet recruiting |
| Research Site | Dallas | Texas | 75235 | Not yet recruiting |
| Research Site | Houston | Texas | 77030 | Not yet recruiting |
| Research Site | Fairfax | Virginia | 22031 | Not yet recruiting |
| Research Site | Puyallup | Washington | 98373 | Not yet recruiting |
| Research Site | Seattle | Washington | 98101 | Not yet recruiting |
| Research Site | Seattle | Washington | 98104 | Not yet recruiting |
| Research Site | Milwaukee | Wisconsin | 53226 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
Recently updated Newly Diagnosed Multiple Myeloma trials
Other public records listing Newly Diagnosed Multiple Myeloma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07601100: Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Not yet recruiting
- NCT06679101: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) Recruiting
- NCT07247097: ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Not yet recruiting
- NCT04052880: Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07764978, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Aug 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07764978 live on ClinicalTrials.gov.